Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Payne, Rebecca PLonget, Stephanie
Austin, James A
Skelly, Donal T
Dejnirattisai, Wanwisa
Adele, Sandra
Meardon, Naomi
Faustini, Sian
Al-Taei, Saly
Moore, Shona C
Tipton, Tom
Hering, Luisa M
Angyal, Adrienn
Brown, Rebecca
Nicols, Alexander R
Gillson, Natalie
Dobson, Susan L
Amini, Ali
Supasa, Piyada
Cross, Andrew
Bridges-Webb, Alice
Reyes, Laura Silva
Linder, Aline
Sandhar, Gurjinder
Kilby, Jonathan A
Tyerman, Jessica K
Altmann, Thomas
Hornsby, Hailey
Whitham, Rachel
Phillips, Eloise
Malone, Tom
Hargreaves, Alexander
Shields, Adrian
Saei, Ayoub
Foulkes, Sarah
Stafford, Lizzie
Johnson, Sile
Wootton, Daniel G
Conlon, Christopher P
Jeffery, Katie
Matthews, Philippa C
Frater, John
Deeks, Alexandra S
Pollard, Andrew J
Brown, Anthony
Rowland-Jones, Sarah L
Mongkolsapaya, Juthathip
Barnes, Eleanor
Hopkins, Susan
Hall, Victoria
Dold, Christina
Duncan, Christopher J A
Richter, Alex
Carroll, Miles
Screaton, Gavin
de Silva, Thushan I
Turtle, Lance
Klenerman, Paul
Dunachie, Susanna
Publication date
2021-10-16Subject
Microbiology. ImmunologyClinical pathology
Genetics
Public health. Health statistics. Occupational health. Health education
Metadata
Show full item recordAbstract
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced protection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589 individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike protein. NAb levels were higher after the extended dosing interval (6-14 weeks) compared with the conventional 3- to 4-week regimen, accompanied by enrichment of CD4+ T cells expressing interleukin-2 (IL-2). Prior SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective immunogenic protocol.Citation
Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, Meardon N, Faustini S, Al-Taei S, Moore SC, Tipton T, Hering LM, Angyal A, Brown R, Nicols AR, Gillson N, Dobson SL, Amini A, Supasa P, Cross A, Bridges-Webb A, Reyes LS, Linder A, Sandhar G, Kilby JA, Tyerman JK, Altmann T, Hornsby H, Whitham R, Phillips E, Malone T, Hargreaves A, Shields A, Saei A, Foulkes S, Stafford L, Johnson S, Wootton DG, Conlon CP, Jeffery K, Matthews PC, Frater J, Deeks AS, Pollard AJ, Brown A, Rowland-Jones SL, Mongkolsapaya J, Barnes E, Hopkins S, Hall V, Dold C, Duncan CJA, Richter A, Carroll M, Screaton G, de Silva TI, Turtle L, Klenerman P, Dunachie S; PITCH Consortium. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. 2021 Nov 11;184(23):5699-5714.e11. doi: 10.1016/j.cell.2021.10.011. Epub 2021 Oct 16Type
ArticleOther
Additional Links
https://www.sciencedirect.com/journal/cellPMID
34735795Journal
CellPublisher
Cell Pressae974a485f413a2113503eed53cd6c53
10.1016/j.cell.2021.10.011